Empty vials containing a dose of the Johnson & Johnson coronavirus COVID-19 vaccine lie on a table as South Africa advances its inoculation campaign at Klerksdorp Hospital on February 18, 2021.
Phill Magakoe | AFP | fake images
Two trial participants suffered severe allergic reactions shortly after receiving Johnson & Johnson’s Covid-19 vaccine, a J&J scientist told an FDA panel on Friday.
J&J was first informed Wednesday about the allergic reactions, Macaya Douoguih, head of clinical development and medical affairs for J & J’s vaccine division, Janssen, told the FDA’s Advisory Committee on Vaccines and Related Biologicals.
One of the people was participating in an ongoing trial in South Africa and developed anaphylaxis, a severe and life-threatening allergic reaction, after receiving the vaccine, he said.
He did not elaborate on the reaction of the second person.
“We will continue to closely monitor these events,” he told the panel.
Previously, there were no reports of anaphylaxis in the J&J clinical trial. The Centers for Disease Control and Prevention are monitoring events such as states and pharmacies that implement the Pfizer and Moderna vaccines.
There have been 46 reports of anaphylaxis in those who received the Pfizer vaccine and 16 cases in those who received the Moderna vaccine, according to a CDC report released Feb. 16. vaccine.
The CDC is asking healthcare providers to monitor patients for 15 minutes after vaccination and 30 minutes for those who have a history of allergic reactions.
If someone has a severe allergic reaction after receiving the first dose of the Covid-19 vaccine, the CDC recommends that they not receive the second dose, even if the allergic reaction was not severe enough to require emergency care.